# ![@AnnaFlorcia Avatar](https://lunarcrush.com/gi/w:26/cr:twitter::1461001482.png) @AnnaFlorcia AnnaF

AnnaF posts on X about $lqda, in the, $uthr, data the most. They currently have [-----] followers and [---] posts still getting attention that total [-----] engagements in the last [--] hours.

### Engagements: [-----] [#](/creator/twitter::1461001482/interactions)
![Engagements Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::1461001482/c:line/m:interactions.svg)

- [--] Week [------] +19%
- [--] Month [------] +2.70%
- [--] Months [-------] +76%
- [--] Year [---------] +883%

### Mentions: [--] [#](/creator/twitter::1461001482/posts_active)
![Mentions Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::1461001482/c:line/m:posts_active.svg)

- [--] Week [--] -24%
- [--] Month [--] +63%
- [--] Months [---] +93%
- [--] Year [---] +1,062%

### Followers: [-----] [#](/creator/twitter::1461001482/followers)
![Followers Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::1461001482/c:line/m:followers.svg)

- [--] Week [-----] +0.71%
- [--] Month [-----] +3.70%
- [--] Months [-----] +105%
- [--] Year [-----] +408%

### CreatorRank: [-------] [#](/creator/twitter::1461001482/influencer_rank)
![CreatorRank Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::1461001482/c:line/m:influencer_rank.svg)

### Social Influence

**Social category influence**
[stocks](/list/stocks)  10% [finance](/list/finance)  10% [cryptocurrencies](/list/cryptocurrencies)  1%

**Social topic influence**
[$lqda](/topic/$lqda) #2, [in the](/topic/in-the) 11%, [$uthr](/topic/$uthr) 8%, [data](/topic/data) 7%, [the first](/topic/the-first) 6%, [ceo](/topic/ceo) 6%, [math](/topic/math) 5%, [market cap](/topic/market-cap) 5%, [growth](/topic/growth) 4%, [money](/topic/money) 4%

**Top accounts mentioned or mentioned by**
[@plus212bio](/creator/undefined) [@toconnell](/creator/undefined) [@billybobbleach](/creator/undefined) [@usfda](/creator/undefined) [@lqda_bull1](/creator/undefined) [@elliott_wagner](/creator/undefined) [@alphahunte79332](/creator/undefined) [@meremrtl](/creator/undefined) [@mbamcnulty](/creator/undefined) [@svixenjoyoor](/creator/undefined) [@deitaone](/creator/undefined) [@tommythompsonwi](/creator/undefined) [@uthrmed](/creator/undefined) [@sleepingbear84](/creator/undefined) [@mauriceontw](/creator/undefined) [@smallcapshark](/creator/undefined) [@mc154mc154](/creator/undefined) [@amheshay](/creator/undefined) [@smithy05261244](/creator/undefined) [@biotech2k1](/creator/undefined)

**Top assets mentioned**
[Liquidia Corporation Common Stock (LQDA)](/topic/$lqda) [United Therapeutics, Corp. (UTHR)](/topic/$uthr) [Insmed, Inc. (INSM)](/topic/$insm) [2025 (2025)](/topic/$2025) [Merck & Co., Inc. (MRK)](/topic/$mrk)
### Top Social Posts
Top posts by engagements in the last [--] hours

"Your math looks good to me. Outside of NA will provide another 20% boost. Over 20m 6MWD at [--] weeks will be enough for the FDA and doctors. If [--] weeks can show continuation like in Ph2 it's a huge bonus. The CT imaging for [---] patients is what's going to really impress everyone. I've never seen anyone show branch growth like this and it's enough to have me thinking "drug works". https://twitter.com/i/web/status/2019581917490979302 https://twitter.com/i/web/status/2019581917490979302"  
[X Link](https://x.com/AnnaFlorcia/status/2019581917490979302)  2026-02-06T01:20Z [----] followers, [----] engagements


"@AlphaHunte79332 The On-Sale Bar takes care of everything does it not Andrews stated there is proof of prior sale in the trial"  
[X Link](https://x.com/AnnaFlorcia/status/2022401951036743884)  2026-02-13T20:06Z [----] followers, [---] engagements


"$UTHR market cap is $22B $LQDA market cap is $2.6B UTC makes almost all its money from Tyvaso DPI and Yutrepia is better. ASCENT study proved that undeniably. UTC started to see that and started a campaign to copy Yutrepia dosing along with lies. It makes no sense to me for the better product to be evaluated at 88% less. It's not like doctors can't prescribe Yutrepia for IPF in the near future. $LQDA has a next Gen inhaler L606 that will make UTC obsolete in [--] years. This market is broken. 😢 https://twitter.com/i/web/status/2008585324881117672"  
[X Link](https://x.com/AnnaFlorcia/status/2008585324881117672)  2026-01-06T17:03Z [----] followers, [----] engagements


"Another $LQDA hit piece by @meremrtl He is a paid shill. Wrote attacks on $GOSS too yesterday. When Yutrepia does over $100M in Q4 he will just come up with new reasons to put out a sell rating. Take notice of the lack of ASCENT or L606 study data in his report. Stephen how are you not ashamed of yourself Do you have no dignity You wouldn't dare write a piece on UTC. $LQDA at $2.7B is not justified but UTC at $22B is PRINT technology proved Yutrepia is better in ASCENT trial L606 is next Gen and can become gold SoC in 3-4 years. TPIP hasn't proven much and failed in PH-ILD P2. UTC doesn't"  
[X Link](https://x.com/AnnaFlorcia/status/2008923977562181855)  2026-01-07T15:29Z [----] followers, [----] engagements


"$LQDA short-seller report from MDC final thoughts: "While we strongly believe that the '793 Patent should not be considered as Prior Art we remain somewhat uncertain as to what that will mean for the conclusion of the upcoming Ruling. We believe that Liquida had a good "On-Sale Bar" argument to all asserted Claims other than Claim [--] and we note Judge Andrews' prior findings with regard to a "dry powder" in his Trial Opinion (D.E. 433) in Case #20-0755. Overall we still lean in the direction of Judge Andrews likely finding that at least one asserted Claim of '327 Patent is Valid and Infringed"  
[X Link](https://x.com/AnnaFlorcia/status/2019129357298724954)  2026-02-04T19:22Z [----] followers, [----] engagements


"$LQDA MDC full report for all those asking. Absolutely nothing new. The "On-Sale Bar" is all that is needed to invalidate '327"  
[X Link](https://x.com/AnnaFlorcia/status/2019136911554883657)  2026-02-04T19:52Z [----] followers, [----] engagements


"It has no effect on any prostacyclin drugs. It's actually good news for trepostinil if $GOSS Seralutinib has a positive Ph3 readout as patients will stay longer on prostacyclins. It's just like Sota good for everyone especially the patients. You don't need to hedge $LQDA ever. Small royalties is the worst case scenario and Q1 will be spectacular. Yutrepia + Sota is a match made in heaven. My gut feeling tells me Seralutinib works not as fast as Sota possibly but will have a place in the market. AE profile is great much better than Sota. Any disease modifying drug is welcomed by doctors and"  
[X Link](https://x.com/AnnaFlorcia/status/2020257549027873031)  2026-02-07T22:05Z [----] followers, [----] engagements


"@Plus212Bio @BillyBobBleach This is wrong information. Late breaking abstracts and data come to these conferences all the time"  
[X Link](https://x.com/AnnaFlorcia/status/2021263516682858715)  2026-02-10T16:42Z [----] followers, [---] engagements


"@Plus212Bio @BillyBobBleach I don't know maybe I'm wrong. 🤷 American Thoracic Society Call for Late Breaking Abstracts https://share.google/7yTRoJHvFEv2YtDCJ https://share.google/7yTRoJHvFEv2YtDCJ"  
[X Link](https://x.com/AnnaFlorcia/status/2021283784239567109)  2026-02-10T18:03Z [----] followers, [---] engagements


"Andrews understands the logistics. If his decision had a chance of Yutrepia being removed for PH-ILD patients he would feel obligated to get his decision out ASAP like he did for [---]. 3000-3500 patients on Yutrepia right now. 25% is around [---] PH-ILD patients that would need to stop treating. 3/4 are naive who didn't come from Tyvaso that's [---] dying patients that would get downgraded. A lot on his shoulders and he will do the right thing. No matter what UTC says we have enough proof now to conclude Yutrepia is superior in PH-ILD (ASCENT data)."  
[X Link](https://x.com/AnnaFlorcia/status/2022352875712843870)  2026-02-13T16:51Z [----] followers, [---] engagements


"I'm confident not even $INSM TPIP once a day can achieve these levels of 6MWD. $LQDA Yutrepia is just too good and it's market is not going anywhere bookmark it. This is absolutely unbelievably amazing for PH-ILD patients. $LQDA Yutrepia achieved as high as 150M at week [--]. 40% achieved higher than 50M. https://t.co/irRE5RC7jU This is absolutely unbelievably amazing for PH-ILD patients. $LQDA Yutrepia achieved as high as 150M at week [--]. 40% achieved higher than 50M. https://t.co/irRE5RC7jU"  
[X Link](https://x.com/anyuser/status/1983245530559119718)  2025-10-28T18:52Z [----] followers, [----] engagements


"Lots of smart doctors but some are buying what UTC salesforce are selling "Yutrepia could be pulled off the market for PH-ILD". Thanks for sharing another $LQDA Yutrepia success story. Patients need the absolute best and no fraudulent patent should get in the way. ❤ $LQDA update: spoke to her today for the first time since June. She tried Tyvaso but had to quit after a month- the cough was too much. Early last month her pulmonologist started her on Yutrepia and she said it's noticeably better. Still has a cough with the first morning dose $LQDA update: spoke to her today for the first time"  
[X Link](https://x.com/AnnaFlorcia/status/2022415263866720488)  2026-02-13T20:59Z [----] followers, [----] engagements


"$LQDA Q3 prediction: [--]. 2000-2500 scripts. I'm not sure if they will provide numbers up to November or a week into. Anything over [----] is extraordinary for Yutrepia's first official full Q on the market. [--]. $30-35M in Yutrepia sales. I have attached $VRNA sales as guidance and I expect $LQDA to follow. Yutrepia did $6.5M in Q2. First month free has an effect when you are loading and converting. [--]. [-----] to [-----] EPS. Not profitable yet but Q4 for sure. All my numbers are conservative and realistic. Can it be 2500-3000 and + EPS Sure. https://twitter.com/i/web/status/1975963537773322313"  
[X Link](https://x.com/anyuser/status/1975963537773322313)  2025-10-08T16:36Z [----] followers, 35.5K engagements


"@mbamcnulty @svix_enjoyoor It's only been [--] months. It takes 12-18 months for a paradigm shift. $LQDA Yutrepia will be used for IPF/PPF once FDA approves Tyvaso for it. Tyvaso Nebulizer is cumbersome and off-label is easy for many doctors. Ask yourself why didn't UTC run IPF/PPF trials using Tyvaso DPI"  
[X Link](https://x.com/AnnaFlorcia/status/2010376261055725840)  2026-01-11T15:40Z [----] followers, [---] engagements


"$LQDA slide update shows [----] starts at the end of December and not [----]. 85% conversion rate is unbelievable. RJ expects over $1B in [----]. [---] update: Team is very confident"  
[X Link](https://x.com/AnnaFlorcia/status/2011615634149589254)  2026-01-15T01:45Z [----] followers, 17.8K engagements


"@DeItaone In other words: Vaccines dont work well enough"  
[X Link](https://x.com/AnnaFlorcia/status/1476604153782755333)  2021-12-30T17:20Z [----] followers, [--] engagements


"Scathing article describing how $UTHR manipulated the FDA against $LQDA: https://substack.com/inbox/post/149075832utm_campaign=unknown&utm_medium=web https://substack.com/inbox/post/149075832utm_campaign=unknown&utm_medium=web"  
[X Link](https://x.com/anyuser/status/1838222713657372749)  2024-09-23T14:23Z [----] followers, 100.7K engagements


"It's so important to not just retweet but to read the article and then send it to Congress/FDA personnels. The article will explain what we are fighting for we are past just making money on the stock. Patients need your help $LQDA needs your help"  
[X Link](https://x.com/AnnaFlorcia/status/1838950746290807078)  2024-09-25T14:36Z [----] followers, [----] engagements


"Here is @US_FDA Lawyers begging the courts to not interfere with the way FDA does things in case they messed up. You don't ask in this matter if you didn't fabricate exclusivity and did not make a deal with $UTHR. We need to get Congressmen/women involved ASAP. $LQDA"  
[X Link](https://x.com/anyuser/status/1849472489174245708)  2024-10-24T15:26Z [----] followers, [----] engagements


"$LQDA MATH: UTC market cap over $18B UTC Q3 earnings showing 30%+ increase q/q for Tyvaso Yutrepia can replace both Nebulizer and DPI Yutrepia is as good if not better in ILD $LQDA market cap $900M $LQDA has L606 next gen UTC does not"  
[X Link](https://x.com/anyuser/status/1854916050325848191)  2024-11-08T15:57Z [----] followers, 14.2K engagements


"Meet @TommyThompsonWI and Louis Sullivan they are two former secretary of HHS now on the board of UTC. No wonder UTC is receiving improper exclusivity and other favors on Tyvaso and it's weak patents. @US_FDA #Corruption $LQDA"  
[X Link](https://x.com/anyuser/status/1858537696949334199)  2024-11-18T15:48Z [----] followers, [----] engagements


"$LQDA updated ASCENT trial data shows no dropouts so far zero none compared to Tyvaso DPI of over 50%"  
[X Link](https://x.com/AnnaFlorcia/status/1879592500652134753)  2025-01-15T18:12Z [----] followers, 27.9K engagements


"I'm not sure if many are understand today's ASCENT trial data from $LQDA. Tyvaso DPI had 69% (18 out of [--] patients) drop out in naive ILD trial. Yutrepia used on [--] naive ILD patients had zero dropouts at [--] days. Tyvaso DPI patients dropped out as early as day [--]. Median was [--] days. This is almost a apples to apples comparison. Any doctor will look at this data even though trial is not complete and say yutrepia works better for naive ILD patients. PRINT technology just showed it's true colors"  
[X Link](https://x.com/anyuser/status/1879604647943352655)  2025-01-15T19:00Z [----] followers, 13.6K engagements


"I've gone through hell and back with $LQDA just ask @T_OConnell. At this point I will go down with the ship or wait till I'm rewarded. I was going to sell between $20-25 but after seeing ASCENT trial data be so amazing so far I know we have a clear winner. Any competition is 3-5 years away and $LQDA has L606 coming by then. I am hoping FDA and judges involved open their eyes and approve Yutrepia end of May and kill [---]. Doctors will soon realize the reality of PRINT technology and make Yutrepia the gold standard for ILD. Market is growing and $LQDA has a clear winner with the best CEO in the"  
[X Link](https://x.com/anyuser/status/1887190961849041311)  2025-02-05T17:26Z [----] followers, [----] engagements


"$LQDA insight from a professional friend:"  
[X Link](https://x.com/anyuser/status/1894832704337699064)  2025-02-26T19:31Z [----] followers, [----] engagements


"$LQDA Update from earnings and conference: -Mean 6MWD in the first [--] patients in ASCENT trial was 26.4M at week [--] compared to 15M in tyvaso trial. Achieved thanks to higher dosing. -Enrollment will be completed in the next few weeks. -Doctors involved in the ASCENT Trials all over US are leaders that will be on panels in the future. First hand experience on how Yutrepia is superior. - More data in late May at ATS in San Francisco. -No legal barriers for approval of Yutrepia in May. -Will be sending FDA final approval request letter [--] months before exclusivity date ends (May 23rd) next week."  
[X Link](https://x.com/AnnaFlorcia/status/1902407228927443285)  2025-03-19T17:10Z [----] followers, 24.4K engagements


"Nothing in UTC earnings report that would justify $LQDA selling yesterday. Nothing in the courts. I read the court transcript and it's just discussion of PI timeline. Everything we already knew. Tyvaso DPI growth is so impressive. Yutrepia is going to be a money maker like no other. ATS data will be the difference maker. That liquidation yesterday was forced no cause for concern"  
[X Link](https://x.com/anyuser/status/1917547245018440132)  2025-04-30T11:51Z [----] followers, [----] engagements


"$LQDA "Since 02/2020 when we filed our NDA United has asserted five patents against us in federal court. They have sued the FDA twice to prevent the approval of Yutrepia. They have filed a citizens petition to the FDA against Yutrepia to prevent the approval. Theyve asked for two preliminary injunctions on the patent cases and theyve asked for two preliminary injunctions against the FDA. So if youre not counting at home that is [--] unique instances of them trying to prevent Yutrepia from getting to market. So to answer your question specifically are we not surprised that they brought this suit"  
[X Link](https://x.com/anyuser/status/1922667034560835752)  2025-05-14T14:55Z [----] followers, 39.9K engagements


"Never forget Roger Jeffs ( $LQDA CEO) was president and co-CEO of UTC. This is all you need to know and remember. RJ knows what he is doing and where he needs to go. He it's some new kid on the block. He wasn't fired he stepped down along with others. In RJ we must trust"  
[X Link](https://x.com/AnnaFlorcia/status/1922704754754322884)  2025-05-14T17:25Z [----] followers, [----] engagements


"Congratulations to all $LQDA longs. This is just the beginning. Risk is still there but very limited after everything we have gone through. ATS is next week and we will have more complete ASCENT trial [--] week data on the first [--] patients. Approval is on Saturday the 24th"  
[X Link](https://x.com/AnnaFlorcia/status/1922745070979010711)  2025-05-14T20:05Z [----] followers, [----] engagements


"There is a TRO/PI hearing tomorrow at 2pm ET that UTC motioned for but it's the fourth attempt in [--] different courts by UTC and if judge grants it (LQDA argument rock solid) than the only explanation is a bribe. All previous three have been denied. $LQDA is fighting evil on multiple levels"  
[X Link](https://x.com/anyuser/status/1924536097746608382)  2025-05-19T18:42Z [----] followers, 12.6K engagements


"Hon. Thomas D. Schroeder do the right thing today or you will have to answer to all $LQDA followers and all PAH PH-ILD patients and their family members"  
[X Link](https://x.com/AnnaFlorcia/status/1925930902460199222)  2025-05-23T15:04Z [----] followers, [----] engagements


"$LQDA Yutrepia APPROVED for PAH and PH-ILD https://liquidia.com/news-releases/news-release-details/us-fda-approves-liquidias-yutrepiatm-treprostinil-inhalation https://liquidia.com/news-releases/news-release-details/us-fda-approves-liquidias-yutrepiatm-treprostinil-inhalation"  
[X Link](https://x.com/AnnaFlorcia/status/1925982529091227831)  2025-05-23T18:29Z [----] followers, 10.3K engagements


"$LQDA Dr.Nicholas Hill Chief Pulmonary Critical Care & Sleep Division Professor of Medicine atTufts University School of Medicine and Principal Investigator on the Phase3 INSPIRE study said: I am so pleased that patients with PAH and PH-ILD now have this newly introduced option for inhaled treprostinil. Having treated patients for more than six years in Liquidias INSPIRE and extension studies I am confident in the safety tolerability and dosing that YUTREPIA offers. The low-effort inhalation device used to deliver YUTREPIA may make it easier to start and maintain patients on treatment"  
[X Link](https://x.com/AnnaFlorcia/status/1925983246958870999)  2025-05-23T18:32Z [----] followers, [----] engagements


"$LQDA has new Yutrepia website: https://yutrepia.com/ https://yutrepia.com/"  
[X Link](https://x.com/AnnaFlorcia/status/1926024981919490261)  2025-05-23T21:18Z [----] followers, [----] engagements


"$LQDA Math: Tyvaso did $466M in sales in Q1 that's $1.86B/y and growing. Let's say $LQDA takes only 20% of that = $373M. $UTHR has a 5X multiple right now and it's been as high as 7X multiple. $373M x [--] = $1.9B market cap. That's $23 a share min. I think they will eventually take 50% of all new patients which would be over $50 a share at current O/S shares. $50 after a small offering in the future. RJ and team confident no more money is needed before reaching profitability in Q3/4. 5X multiple is low due to market conditions. L606 hasn't been factored into stock price YET"  
[X Link](https://x.com/anyuser/status/1927414796451819741)  2025-05-27T17:21Z [----] followers, 23.9K engagements


"I'm not even factoring in the fact that $LQDA can take 100%+. The ILD market is 80% untapped. Yutrepia is superior with dosing and results it can out sell Tyvaso on all new patients and ones who dropped out of Tyvaso DPI. This is RJs goal and thanks to UTC they have grown awareness of the disease and treatment. Calculations above are absolutely worst case scenario"  
[X Link](https://x.com/AnnaFlorcia/status/1927416067791475127)  2025-05-27T17:26Z [----] followers, [----] engagements


"$LQDA wins and wins big on [---] patent. Here is why UTC [---] patent is complete garbage and I'm so happy the judge states so:"  
[X Link](https://x.com/AnnaFlorcia/status/1928570738207772823)  2025-05-30T21:54Z [----] followers, 21.4K engagements


"$LQDA Yutrepia is truly unique. I remember 3-4 years ago taking a deep dive into PRINT technology when nobody was talking about it. I kept asking myself why hasn't anyone else thought about mimicking nature Your body can't detect pollen or any nature air born particles. It can penetration deep into your lungs and cause allergies and irritation effortlessly. I knew then that PRINT technology was going to showcase itself at some point. We already see this with only [--] patients at [--] weeks. Not a single dropout even if we have a few going forward it's still better than what Tyvaso DPI was able to"  
[X Link](https://x.com/anyuser/status/1929257108010311890)  2025-06-01T19:21Z [----] followers, 10.1K engagements


"$LQDA presentation today at Jeffries was exciting. [---] week ascent trial for all patients in August/September. -RJ said it's just as good as the early data. -Prescription were filled yesterday. [----] patent trial is easy win opinion in Q4. -L606 OL data looking good. Will be next gen. -TPIP is not [--] hours stable might as well use Yutrepia. -No need for offering $200M+ in bank. Will be profitable EOY. -Yutrepia on path to dominate $4B+/year market"  
[X Link](https://x.com/AnnaFlorcia/status/1930290792310157649)  2025-06-04T15:49Z [----] followers, 31.6K engagements


"$LQDA CFO: "Our early momentum and strong financial position reinforce our belief in Liquidias ability to achieve profitability without the need for additional capital. This reads - Strong early momentum - No more offerings"  
[X Link](https://x.com/AnnaFlorcia/status/1937258394810999249)  2025-06-23T21:16Z [----] followers, 14.1K engagements


"$LQDA Short Interest is off the charts. 😲 🚨 We are over 20M right now most likely. Almost 25% of the total shares is short. Almost 30% of the float is short. Institutions own 58M share that mean almost 80% of the public float is short"  
[X Link](https://x.com/AnnaFlorcia/status/1938010935509324120)  2025-06-25T23:06Z [----] followers, [----] engagements


"Knowledge of the following is critical: [--]. $LQDA PRINT technology advantages [--]. Who the CEO is [--]. Market size of PAH and PH-ILD [--]. ASCENT trial data so far [--]. Tyvaso DPI dropout rate in ILD [--]. L606 and its potential [--]. $LQDA market cap compared to UTHR and MNKD Let the shorts short. Let the paid advisors continue to bash Yutrepia. I knows the story and the main characters and will not sell a single share under $30"  
[X Link](https://x.com/AnnaFlorcia/status/1939831203085131841)  2025-06-30T23:39Z [----] followers, [----] engagements


"Farallon Capital buy 6.8M shares of $LQDA Who's next"  
[X Link](https://x.com/anyuser/status/1943805022015566009)  2025-07-11T22:50Z [----] followers, [----] engagements


"300K share buying in $LQDA at open pushed stock up nearly $1. Institution buying is not done. Shorts are still not done"  
[X Link](https://x.com/AnnaFlorcia/status/1944770129813975380)  2025-07-14T14:45Z [----] followers, [----] engagements


"$LQDA Short interest hits new highs again 🚨🚨"  
[X Link](https://x.com/anyuser/status/1948483967516123212)  2025-07-24T20:42Z [----] followers, 10.3K engagements


"$LQDA Math for anyone who missed it. I have a strong feeling Yutrepia is going to take well over 20%. Stock under $30 is cheap. Expecting 300-500 scripts for June+July. I don't think we see $30 anytime soon. Just too many shorts concerns of [---] patent outcome and ASCENT trial data. [---] patent has 10-15% chance of going against $LQDA. RJ has already hinted at great ASCENT trial [--] week data. A slow grind up like $VRNA is what I'm hoping for after Q2 earnings. L606 still hasn't been given any value. We will get more data later on this year probably. $LQDA Math: Tyvaso did $466M in sales in Q1"  
[X Link](https://x.com/anyuser/status/1949194208700751895)  2025-07-26T19:44Z [----] followers, 13.5K engagements


"🔥💥💯 $LQDA https://www.bleeckerstreetresearch.com/research/uthr-lqda https://www.bleeckerstreetresearch.com/research/uthr-lqda"  
[X Link](https://x.com/anyuser/status/1950196684635463704)  2025-07-29T14:08Z [----] followers, [----] engagements


"This is Andreas Argyrides who gave $LQDA a $6 PT. He is related to Alex. 😂"  
[X Link](https://x.com/anyuser/status/1950240343221555342)  2025-07-29T17:01Z [----] followers, [----] engagements


"I was just informed $LQDA is forming a cup and handle. ☕ I guess it's coffee time. ☕"  
[X Link](https://x.com/anyuser/status/1952429734484496384)  2025-08-04T18:01Z [----] followers, [----] engagements


"I know many are worried about $LQDA in the [---] patent trial. I'm here to tell you DON'T BE. [--]. The worst case scenario is a 10% Royalty. This royalty will be for a few years till patent expires. [--]. We can appeal it and even try to invalid [---] patent with PTAB. $LQDA needs to focus on taking as much of the market they can. ASCENT trial will be the key according to doctors. CEO RJ has already hinted at full [--] week data being just as good as the first [--] patients. Listen to the Jefferies conference he did back in early June. Jefferies Global Healthcare Conference Liquidia Corporation 327"  
[X Link](https://x.com/anyuser/status/1952741374509429109)  2025-08-05T14:39Z [----] followers, [----] engagements


"On Tuesday $LQDA will report the first Q after approval. What to expect and not to expect on earnings report and CC Expect: [--]. Big loss for the Q. Negative earnings. EPS of [-----] or lower. Revenue under $4M possibly. [--]. Prescription starts for June and July. DON'T Expect: [--]. Guidance. No guidance will be given for this year. [--]. Data on any trials. Keep expectations low. I know everyone is talking about how stock could be up XX% I doubt it will. This stock has always done the opposite of what you expect. It's about the long game think Q1 of next year not short term. I expect start numbers of"  
[X Link](https://x.com/anyuser/status/1954209786062586334)  2025-08-09T15:54Z [----] followers, [----] engagements


"$LQDA with strong start Liquidia Corporation Reports Second Quarter [----] Financial Results and Provides Corporate Update Liquidia Corporation https://share.google/7Zji1cS1SW3wocFAZ https://share.google/7Zji1cS1SW3wocFAZ"  
[X Link](https://x.com/anyuser/status/1955216256526860420)  2025-08-12T10:34Z [----] followers, [----] engagements


"$LQDA ASCENT Trial update. 31.5M Median 6MWD at [--] weeks"  
[X Link](https://x.com/anyuser/status/1955217881257611726)  2025-08-12T10:40Z [----] followers, [----] engagements


"$LQDA CEO Roger Jeffs is a 🐐 "In the [--] weeks since approval weve recorded over [---] unique patient prescriptions leading to more than [---] patient starts. This initial demand has exceeded my own high expectations.""  
[X Link](https://x.com/AnnaFlorcia/status/1955221680324026408)  2025-08-12T10:55Z [----] followers, [----] engagements


"$LQDA story has created a lot of clowns today. Here is the 🐐 with his $6 PT"  
[X Link](https://x.com/AnnaFlorcia/status/1955226054660075556)  2025-08-12T11:13Z [----] followers, [----] engagements


"$LQDA Hall of shame. Posts below are for entertainment purposes only. Many clowns many doubters and many haters. None have been forgotten none will ever be forgiven. Chose wisely who you listen to on the Internet. Most are full of 💩"  
[X Link](https://x.com/AnnaFlorcia/status/1955234170466341052)  2025-08-12T11:45Z [----] followers, [----] engagements


"If you sell $LQDA under $30 you will regret it in the near future. Let the shorts ❤🔥 in hell. 25% of all shares are short. Don't let them off so easily"  
[X Link](https://x.com/AnnaFlorcia/status/1955256036438446245)  2025-08-12T13:12Z [----] followers, [----] engagements


"$LQDA to host a R&D day in the fall for L606. RJ is as excited for L606 as he is for Yutrepia. L606 hasn't even been valued into the stock cap"  
[X Link](https://x.com/AnnaFlorcia/status/1955256873738723422)  2025-08-12T13:15Z [----] followers, [----] engagements


"List of extremely smart dedicated and caring people on this platform that I have had the pleasure of interacting and brainstorming with regarding $LQDA: @T_OConnell @sleepingbear84 @MauriceOnTW @small_capshark @mc154mc154 And many more directly and indirectly. ❤"  
[X Link](https://x.com/AnnaFlorcia/status/1955282110169612490)  2025-08-12T14:55Z [----] followers, [----] engagements


"$LQDA Thoughts: UTC gets [----] scripts a Q (new + refills). UTC $14B evaluation Tyvaso+DPI is 60% of revenue $8.4B of cap. Yutrepia can take 50% easily by as early as [----] giving $LQDA $4.2B cap. PH-ILD market is where Yutrepia will dominate and control over 50%. This market is only 20% penetrated. 60K patients is the estimate. $LQDA will keep growing while UTC shrinks. Tyvaso DPI still valid for PAH. UTC will have to reduce prices to compete but their COGs are higher much higher (check MNKD). L606 has no evaluation yet. Merck is ideal candidate. Buy LQDA for $5B if TPIP works for PAH not a"  
[X Link](https://x.com/AnnaFlorcia/status/1955628544392061403)  2025-08-13T13:52Z [----] followers, [----] engagements


"@T_OConnell"  
[X Link](https://x.com/AnnaFlorcia/status/1955642377001214050)  2025-08-13T14:47Z [----] followers, [----] engagements


"I've been asked many times now from $LQDA holders if $INSM TPIP is a threat. No. L606 will be approved just before TPIP does. TPIP has the same issue as Tyvaso DPI it's not low resistant high flow. Yutrepia is kicking butt cause its easier on the lungs of PH-ILD patients and can be dosed much higher as a result. L606 will be using a next gen portable nebulizer. Sure it's twice a day but I don't think patients or doctors will care. Once when you wake up and once right before bed. The once vs twice a day is nonsense. It will come down to AE/SAE and comfort. Nebulizer have always been easier on"  
[X Link](https://x.com/anyuser/status/1956355975121920456)  2025-08-15T14:03Z [----] followers, [----] engagements


"$LQDA Yutrepia has UTC sales reps worried"  
[X Link](https://x.com/AnnaFlorcia/status/1957148502179615186)  2025-08-17T18:32Z [----] followers, [----] engagements


"Next [--] months of catalysts for $LQDA: -L606 R&D day to showcase data. Fall (Sept/Oct) -More L606 and ASCENT data at CHEST (Oct 19-22) -'327 Patent opinion and conclusion (October) -Q3 earnings ($30-40M maybe more) (November) The show is just starting. Everything above goes well and we will be hearing about potential M&A by end of the year. Q4 in February will showcase profitability for the first time"  
[X Link](https://x.com/AnnaFlorcia/status/1957515289618473457)  2025-08-18T18:49Z [----] followers, [----] engagements


"$LQDA [----] Modeling: 2000-3000 patients on Yutrepia for the year. [----] x $273K = $683M COGS at 3-5% = $655M SG&A = $200M for the year. $655M - $200M = $455M 87M SO -- $455M/87M = $5.23 EPS for the year. 10-15X multiple depending on market conditions $52.30 to $78 stock price for [----]. These are rough numbers without going crazy. [---] in [--] weeks with each week increasing slightly translate to a minimum [----] for [----] on the low side. Taking oral market is a first. L606 still hasn't been priced in and is worth $500M min. Merck would be a fool not to buy $LQDA for $50 this year."  
[X Link](https://x.com/anyuser/status/1958201617679085965)  2025-08-20T16:17Z [----] followers, [----] engagements


"I heard $LQDA Yutrepia is so good that even Martine's daughter is using it"  
[X Link](https://x.com/AnnaFlorcia/status/1960350808127819868)  2025-08-26T14:37Z [----] followers, [----] engagements


""Tyvaso demonstrated superiority over placebo for the change in absolute FVC by [----] mL" Trepostinal is not going anywhere. A huge pool (IPF) just opened up for $LQDA Yutrepia (off-label) and L606. This is truly surprising and incredibly. I'm not sure how UTC pulled it off but Trepostinal is the safest + extremely effective in PAH/PH-ILD and now IPF and possibly PPF"  
[X Link](https://x.com/AnnaFlorcia/status/1962901154058453456)  2025-09-02T15:31Z [----] followers, [----] engagements


"$LQDA is worth vastly more today thanks to UTC. L606 is next gen nebulizer that can capture all of PAH PH-ILD and now IPF market. Buyout of $LQDA just went up significantly. Best in class DPI and nebulizer. Wake up Merck"  
[X Link](https://x.com/anyuser/status/1962906689717575822)  2025-09-02T15:53Z [----] followers, [----] engagements


"$LQDA under $30 right now is like $LQDA at $12 in July. I'm not sure anyone understands or has done the math. 100K patients just entered the trepostinal market. L606 has a strong potential to becoming best in class trepostinal Nebulizer. Yutrepia is already best in class trepostinal DPI. TPIP hasn't proven anything. It's not a nebulizer and it's not low resistance/high flow to treat PH-ILD and IPF correctly. Sotatercept and Seralutinib are not trepostinal replacements. Trepostinal is here to stay and $LQDA has a better product"  
[X Link](https://x.com/anyuser/status/1962926212692771225)  2025-09-02T17:10Z [----] followers, [----] engagements


"$LQDA + $MRK = 💰"  
[X Link](https://x.com/anyuser/status/1962972794544914858)  2025-09-02T20:15Z [----] followers, [----] engagements


"$LQDA L606 path to approval for IPF is much shorter than you think:"  
[X Link](https://x.com/AnnaFlorcia/status/1964762022232592757)  2025-09-07T18:45Z [----] followers, [----] engagements


"$LQDA Yutrepia peak sales will be $1-2B (PAH + PH-ILD). $1B is my min. This is not hard to achieve given growing PH-ILD market oral market transitions (dosing and no GI side effects) Tyvaso nebulizer transitions due to higher dosing taking +70% of Tyvaso DPI in PH-ILD (dosing and cough score) and off-label scrips for IPF. 3-5X peak sales is standard. [--] X $1B is $3B = $35/share. [--] X 2B is $10B = $115/share. I won't even give L606 evaluation just yet. RJ is excited for L606 and we will wait for R&D day"  
[X Link](https://x.com/anyuser/status/1969890945580834987)  2025-09-21T22:26Z [----] followers, [----] engagements


"Possible knock out punch on the '327 patent in $LQDA's favor. Very good news to end that overhang. After the market close Judge Andrews asked for briefing from $LQDA and $UTHR about the recently decided case Bayer versus Mylan that came out yesterday. Here is Gemini's quick take on what this decision means for this '327 case. This is a significant development that provides After the market close Judge Andrews asked for briefing from $LQDA and $UTHR about the recently decided case Bayer versus Mylan that came out yesterday. Here is Gemini's quick take on what this decision means for this '327"  
[X Link](https://x.com/anyuser/status/1971019055458046383)  2025-09-25T01:08Z [----] followers, 17.4K engagements


"A new damning article on $UTHR it's CEO and the lawfare it uses. $LQDA Please repost to expose the evil UTC CEO. https://open.substack.com/pub/charleserussell/p/the-troubling-legacy-of-the-foundingutm_source=share&utm_medium=android&r=2b4gxn https://open.substack.com/pub/charleserussell/p/the-troubling-legacy-of-the-foundingutm_source=share&utm_medium=android&r=2b4gxn"  
[X Link](https://x.com/anyuser/status/1972717065460183477)  2025-09-29T17:36Z [----] followers, [----] engagements


"$LQDA Yutrepia better than Tyvaso DPI says patient doctor nurse and UTC reps"  
[X Link](https://x.com/anyuser/status/1973835616199823516)  2025-10-02T19:40Z [----] followers, [----] engagements


"If $LQDA didn't have a better product this would not be happening. Lawfare is disgusting and at the heart of it all is a disturbed inhuman person. We must continue to fight the good fight. Evil must not prevail. This isn't about making money on the stock anymore it's about getting justice for dying PAH and PH-ILD patients. The RBC analyst with the highest price target on $UTHR (after Oppenheimer) is trotting out this young guy Jacob Skerlow who is a law professor at Illinois to give his take on the $LQDA legal situation. The call is tomorrow. This guy has given some very misinformed views in"  
[X Link](https://x.com/anyuser/status/1980703979685458372)  2025-10-21T18:33Z [----] followers, [----] engagements


"$LQDA Yutrepia ASCENT trial showed no treatment related SAEs or discontinuation due to cough. Tyvaso DPI had 50%+ discontinuation"  
[X Link](https://x.com/anyuser/status/1980721291893305641)  2025-10-21T19:42Z [----] followers, [----] engagements


"$LQDA ASCENT trial actually showed decrease of cough score at [--] weeks"  
[X Link](https://x.com/anyuser/status/1980721721385840687)  2025-10-21T19:43Z [----] followers, [----] engagements


"$LQDA If you remove the first outlier of -77M and do the calculations on n=40 you would get a Mean of 33M 6MWD at [--] weeks. This is exceptional for naive PH-ILD patients. Doctors now have full [--] week data and I wouldn't be surprised to see off-label prescription for IPF in the near future. IPF patients will want a portable DPI over a cumbersome Tyvaso nebulizer"  
[X Link](https://x.com/AnnaFlorcia/status/1980782649267614210)  2025-10-21T23:45Z [----] followers, 20.3K engagements


"Is it a coincidence that everytime $LQDA has a presentation of data like the one on Tuesday somebody comes out with a negative take like RBC and Sherkow It's like a certain evil deranged person is paying for damage control to their subpar drug or upcoming Q results"  
[X Link](https://x.com/AnnaFlorcia/status/1981433380442165296)  2025-10-23T18:51Z [----] followers, [----] engagements


"$LQDA Yutrepia ASCENT study at [--] week had ZERO discontinuation due to the drug. Dosed as high as 185.5mcg"  
[X Link](https://x.com/anyuser/status/1983241313995894846)  2025-10-28T18:35Z [----] followers, [----] engagements


"This is absolutely unbelievably amazing for PH-ILD patients. $LQDA Yutrepia achieved as high as 150M at week [--]. 40% achieved higher than 50M"  
[X Link](https://x.com/anyuser/status/1983244190084649156)  2025-10-28T18:47Z [----] followers, 13.2K engagements


"My final thoughts on $LQDA after today's R&D day: [--]. It would be criminal for Judge Andrews to remove Yutrepia for PH-ILD patients. [--]. I no longer care what else could be coming to the market. TPIP cannot compete with Yutrepia. Efficacy tolerability and titration is more import to most patients than convince of once a day. [--]. L606 has amazing tolerability and safety with such low cough. 6MWD was good but will be much better in a larger placebo controlled study that will mute the outliers. Hoping they pick sicker patients with under 300M 6MWD. Most investors still don't seem to understand the"  
[X Link](https://x.com/AnnaFlorcia/status/1983264288149254205)  2025-10-28T20:07Z [----] followers, 13.8K engagements


"I'm going to revise my estimate before tomorrow's Q3. Yutrepia revenue will be between $40-50M. If the [--] day free voucher was not a thing +EPS. Fortunately for patients it's a thing and I love $LQDA's approach to putting patients before revenue. Scripts will still be 1800+. Stock should trade $30+ as it's blowing away VRNA's start and they fetched $10B. $LQDA Q3 prediction: [--]. 2000-2500 scripts. I'm not sure if they will provide numbers up to November or a week into. Anything over [----] is extraordinary for Yutrepia's first official full Q on the market. [--]. $30-35M in Yutrepia sales. I have"  
[X Link](https://x.com/anyuser/status/1985113649288229019)  2025-11-02T22:35Z [----] followers, 18.8K engagements


"Well done $LQDA. Congratulations to all longs. The real winners are the patients. 💕"  
[X Link](https://x.com/AnnaFlorcia/status/1985316855431708924)  2025-11-03T12:03Z [----] followers, [----] engagements


"$LQDA starting trial shortly for Oral to Yutrepia along with IPF. They are going after everything. 🚨 They know label doesn't matter doctors just want data"  
[X Link](https://x.com/AnnaFlorcia/status/1985340987741479274)  2025-11-03T13:39Z [----] followers, [----] engagements


"$LQDA Yutrepia growth is sustainable and will eventually lead to total market dominance. Smart trial designs to follow in IPF PPF PH-COPD"  
[X Link](https://x.com/AnnaFlorcia/status/1985349452039967231)  2025-11-03T14:12Z [----] followers, [----] engagements


"Here is why I think $LQDA is down 5% instead of being up 20% Rusty (general counsel) messed up with the last two questions leaving a bad taste in everyone's mouth including mine. Instead of being optimistic he stated the worst case scenario is Yutrepia comes off the market. What he should have stated is skinny label which effects only PH-ILD. He did this after RJ explained that Yutrepia can grow in PAH market of $3.5B alone. Liquidia needs to do a PR asap and fire Rusty"  
[X Link](https://x.com/anyuser/status/1985361290794262719)  2025-11-03T14:59Z [----] followers, 15.9K engagements


"BTIG with $49 PT $LQDA"  
[X Link](https://x.com/AnnaFlorcia/status/1985466305508692450)  2025-11-03T21:57Z [----] followers, [----] engagements


"If you remove the first two outliers in the $LQDA [--] week ASCENT you get a 6MWD value of 46m. Placebo has been -10m on average 56m placebo corrected. Tyvaso DPI could only dream TPIP could only dream Seralutinib could only dream and Sotatercept only did [----] meters at [--] weeks so it could also dream 😂"  
[X Link](https://x.com/anyuser/status/1985721653515731100)  2025-11-04T14:51Z [----] followers, 44.9K engagements


"$LQDA '327 patent thread 🧵"  
[X Link](https://x.com/anyuser/status/1986151683605602387)  2025-11-05T19:20Z [----] followers, [----] engagements


"If judge Andrews "skinny label"s $LQDA Yutrepia stock will probably drop 20-30% but is that warranted 75% of current revenue is from PAH. October was their strongest month as growth is just continuing at a rapid rate. Q4 will still be $100M+. L606 is not effected and still the future. PH-ILD patients can still be served off-label cause most centers now have Yutrepia experience with patients. Tyvaso was doing it before it's PH-ILD approval (Read Dr. testimonials in trial transcript). Any drop in stock price is a buying opportunity I've been told and many are hoping for it after the Q3 numbers."  
[X Link](https://x.com/anyuser/status/1988296037560447105)  2025-11-11T17:21Z [----] followers, [----] engagements


"$LQDA Top Investors Caligan who sits on the board hasn't sold a single share. The rest have added"  
[X Link](https://x.com/AnnaFlorcia/status/1988684245150376107)  2025-11-12T19:04Z [----] followers, [----] engagements


"$LQDA Judge Andrews clearly is convinced that Dr. Waxman took Faria-Urbina and probably other papers to UTC CEO where they planned the INCREASE (tyvaso for PH-ILD) study. UTC used other people's research to run a trial and return create [---] patent. Isn't this Prior Art The inventors of the [---] patent weren't even in that meeting. This alone should invalidate [---] complete"  
[X Link](https://x.com/AnnaFlorcia/status/1988823267415847396)  2025-11-13T04:16Z [----] followers, 12.5K engagements


"My [----] $LQDA Yutrepia revenue expectations: Q1: $130M Q2: $185M Q3: $230M Q4: $260M $800M for [----]. These numbers are based on roughly [--] new starts a week and [--] day voucher at 50%. Actually numbers could vary. UTC has roughly 12-15K patients on Tyvaso/DPI and I think we can take at least half of that going into [----] which would generate $1.5B a year. 5X revenue multiple gives you $7.5B market cap. I'm not going to entertain 7X. [----] patients would generate around $1.3B in revenue which is very based if we are at [----] right now. That's a $6.5B evaluation which is over $60 a share."  
[X Link](https://x.com/anyuser/status/2011502220983091535)  2026-01-14T18:14Z [----] followers, [----] engagements

Limited data mode. Full metrics available with subscription: lunarcrush.com/pricing